James Pursley, president of digital health company Hinge Health, sold 33,000 Class A common shares on Aug. 21, 2026, for a total of $2.91 million, according to regulatory filings.
The transactions were executed under a prearranged 10b5-1 trading plan adopted on June 13, 2025, and included four separate blocks at varying price points. The first block of 500 shares was sold for $42,401 at a weighted average price of $84.80, with prices ranging between $84.65 and $85.03. The second block of 6,300 shares fetched $549,559 at an average price of $87.23, with a spread of $86.57 to $87.56. The largest block, 22,789 shares, generated $2.01 million at an average price of $88.25, trading between $87.58 and $88.58. The final block of 3,411 shares totaled $302,561 at an average price of $88.68, with prices between $88.58 and $88.94.
Following the sales, Pursley retained 706,235 direct shares in the company. At the time of reporting, Hinge Health’s stock was trading at $89.98, near its 52-week high of $93.13. InvestingPro classified the stock as overvalued, placing it on its "Most Overvalued" list.
Hinge Health has seen strong performance in recent months, with its stock gaining over 121% in the past six months. The company’s Q2 results exceeded expectations, reporting earnings of $0.59 per share against a Wall Street consensus of $0.13, while revenue rose 53% to $212.8 million. For full-year 2026, management raised both revenue and profit guidance.
The company also announced plans to expand into gastrointestinal health by acquiring Cylinder Health for $105 million. Analysts have adjusted their price targets accordingly, with Citizens raising its target to $107, Truist Securities to $112, and Stifel to $96.
